Technology
As part of advanced scientific endeavors to develop innovative treatments for critical injuries, researchers at Russia’s Penza State University have engineered an experimental collagen sponge designed to stop bleeding, suppress fibrinolysis, and eliminate harmful bacteria simultaneously. According to the press office of the Russian Ministry of Education and Science, the medical creation relies on a lightweight, porous three-dimensional collagen matrix. This specialized structure absorbs fluids with high efficiency, while collagen triggers the body's natural hemostatic mechanisms, establishing ideal conditions for rapid blood clot formation. To reinforce clot stabilization, the sponge incorporates aminocaproic acid, an agent that suppresses plasminogen activation to prevent the dissolution of clots in their early stages. Concurrently, vancomycin and ciprofloxacin compounds ensure prolonged local antibacterial protection against potential infections. Researcher Natalia Starodubova emphasized that the primary challenge involves not only halting bleeding rapidly but also preserving the formed clot, curbing its premature breakdown, and minimizing microbial contamination risks while maintaining optimal tissue interaction. She noted that no existing universal hemostatic agent currently integrates all these properties effectively. The manufacturing process involves preparing the collagen matrix, introducing active ingredients during the swelling phase, and applying freezing followed by freeze-drying to facilitate the controlled release of therapeutic compounds. Rigorous laboratory evaluations validated the material by examining fluid absorption, dynamic substance release, red blood cell interactions, and reabsorption, with scientists currently refining the composition to produce a standardized, reproducible prototype.
